Oprozomib
Oprozomib
Oprozomib (pronunciation: oh-pro-zoh-mib) is a proteasome inhibitor used in the treatment of multiple myeloma and other types of cancer. It is currently in the clinical trial phase and is not yet approved for general use.
Etymology
The name "Oprozomib" is derived from the Greek words "opos" meaning juice and "zomos" meaning boiled, which refers to the drug's mechanism of action in inhibiting the proteasome, a type of protein complex that breaks down unneeded or damaged proteins in the cell.
Mechanism of Action
Oprozomib works by blocking the action of proteasomes in cancer cells. Proteasomes are responsible for breaking down and recycling proteins in cells. By inhibiting their function, oprozomib causes an accumulation of unwanted proteins in the cells, leading to cell death and slowing the growth of cancer cells.
Related Terms
- Proteasome inhibitor: A type of drug that blocks the action of proteasomes in cells.
- Multiple myeloma: A type of blood cancer that affects plasma cells.
- Clinical trial: A research study that tests how well new medical approaches work in people.
See Also
External links
- Medical encyclopedia article on Oprozomib
- Wikipedia's article - Oprozomib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski